Premium functions are now FREE OF CHARGE due to the modification of the investment data Data developments may cause some parts work incorrectly Incorrect sections - Financial statements, Earnings upcoming dates and calendars Please take our apologise. It will be fixed soon

NVO - Novo Nordisk - ADR

Close
139.16
1.640   1.178%

Share volume: 2,714,411
Last Updated: Fri 30 Aug 2024 10:00:02 PM CEST
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) : 0.87%

PREVIOUS CLOSE
CHG
CHG%
$137.52
1.64
1.19%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
48%
Profitability 64%
Dept financing 16%
Liquidity 52%
Performance 40%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
1.60%
1 Month
8.09%
3 Months
5.18%
6 Months
15.75%
1 Year
49.61%
2 Year
168.76%
Key data
Stock price
$139.16
P/E Ratio 
0.00
DAY RANGE
$137.85 - $139.74
EPS 
$0.00
52 WEEK RANGE
$86.02 - $147.60
52 WEEK CHANGE
$0.49
MARKET CAP 
471.770 B
YIELD 
1.04%
SHARES OUTSTANDING 
3.390 B
DIVIDEND
$0.5126
EX-DIVIDEND DATE
08/16/2024
NEXT EARNINGS DATE
11/06/2024
BETA 
0.90
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$2,425,742
AVERAGE 30 VOLUME 
$4,117,273
Company detail
CEO: Lars Fruergaard Joergensen
Region: US
Website: https://www.novonordisk.com/
Employees: 57,089
IPO year: -
Issue type: American Depository Receipt (ADR’s)
Market: NYSE
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, with production facilities in nine countries and affiliates or offices in five countries.

Recent news